Maternal Multiple Sclerosis and Offspring's Developmental and Behavioral Profile: A Case-control Study

Area of Science:

• Neuroscience
• Developmental Psychology
• Immunology

Background:

• Maternal chronic immune and inflammatory conditions can affect newborn development.
• The impact of maternal multiple sclerosis (MS) on offspring neurodevelopment and the effects of pregnancy treatments like Natalizumab are largely unknown.
• Pregnancy is a critical period for neurodevelopmental disorder etiology.

Purpose of the Study:

• To assess the cognitive and behavioral profile of children born to mothers with MS.
• To compare offspring exposed to maternal MS (treated or untreated with Natalizumab) against a control group.
• To investigate the long-term effects of maternal MS and its treatment on child development.

Main Methods:

• Retrospective enrollment of 39 children exposed to maternal MS and 36 control children.
• Standardized evaluation of intellectual quotient, adaptive functioning, and behavioral issues, including autism symptoms.
• Comparison of developmental outcomes between MS-exposed offspring and controls.

Main Results:

• Offspring exposed to maternal MS demonstrated adequate cognitive profiles and good adaptive skills.
• No significant behavioral problems or autism symptoms were observed in any offspring group.
• Cognitive and adaptive scores were comparable between MS-exposed and control groups, irrespective of Natalizumab treatment.

Conclusions:

• Maternal Natalizumab treatment during pregnancy does not appear to influence offspring developmental or behavioral phenotypes.
• Maternal factors related to MS, such as diagnosis age, disease duration, or severity, did not significantly affect offspring outcomes.
• Offspring of mothers with MS exhibit normal developmental trajectories, unaffected by the maternal condition or its treatment.